HN's European Research Council Starting Grant "DrugsInPregnancy" - 639377

Link to this page

HN's European Research Council Starting Grant "DrugsInPregnancy" - 639377

Authors

Publications

Self-reported perinatal depressive symptoms and postnatal symptom severity after treatment with antidepressants in pregnancy: a cross-sectional study across 12 European countries using the Edinburgh Postnatal Depression Scale

Lupattelli, Angela; Twigg, Michael J.; Zagorodnikova, Ksenia; Moretti, Myla E.; Drozd, Mariola; Panchaud, Alice; Rieutord, Andre; Juraski, Romana Gjergja; Odalović, Marina; Kennedy, Debra; Rudolf, Gorazd; Juch, Herbert; Nordeng, Hedvig

(Dove Medical Press Ltd, Albany, 2018)

TY  - JOUR
AU  - Lupattelli, Angela
AU  - Twigg, Michael J.
AU  - Zagorodnikova, Ksenia
AU  - Moretti, Myla E.
AU  - Drozd, Mariola
AU  - Panchaud, Alice
AU  - Rieutord, Andre
AU  - Juraski, Romana Gjergja
AU  - Odalović, Marina
AU  - Kennedy, Debra
AU  - Rudolf, Gorazd
AU  - Juch, Herbert
AU  - Nordeng, Hedvig
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3227
AB  - Purpose: This study aimed at exploring the prevalence of self-reported antenatal and postnatal depressive symptoms by severity across multiple countries and the association between antidepressant treatment in pregnancy and postnatal symptom severity. Materials and methods: This was a multinational web-based study conducted across 12 European countries (n=8069). Uniform data collection was ensured via an electronic questionnaire. Pregnant women at any gestational week and mothers of children with  lt 1 year of age could participate. We used the Edinburgh Postnatal Depression Scale (EPDS) to measure the prevalence of antenatal and postnatal depressive symptoms according to severity, which were corrected by survey weight adjustment (descriptive analysis). Within mothers with a psychiatric disorder (n=173), we estimated the association between antidepressant treatment in pregnancy and postnatal depressive symptom severity, as standardized EPDS mean scores, via the inverse probability of treatment weight (association analysis). Results: In the descriptive analysis (n=8069), the period prevalence of moderate-to-very severe depressive symptoms was higher in the western and eastern regions relative to the northern region, both in the antenatal period (6.8%-7.5% vs 4.3%) and in the postnatal period (7.6% vs 4.7%). One in two mothers with psychiatric disorders used an antidepressant in pregnancy (86 of 173). In the association analysis, women medicated at any time during pregnancy (adjusted beta=-0.34, 95% confidence interval [CI] =-0.66, -0.02) had a significant postnatal symptom severity reduction compared with the nonmedicated counterpart. This effect was larger (beta=-0.74, 95% CI =-1.24, -0.24) when the analysis was restricted to mothers within 6 months after childbirth. Conclusion: The prevalence of self-reported antenatal and postnatal depressive symptoms differs across European countries. Among women with psychiatric disorders, those who had been on treatment with antidepressants during pregnancy were less likely to report postnatal depressive symptoms, particularly within the 6-month period after childbirth, compared with the nonmedicated counterpart.
PB  - Dove Medical Press Ltd, Albany
T2  - Clinical Epidemiology
T1  - Self-reported perinatal depressive symptoms and postnatal symptom severity after treatment with antidepressants in pregnancy: a cross-sectional study across 12 European countries using the Edinburgh Postnatal Depression Scale
VL  - 10
SP  - 655
EP  - 669
DO  - 10.2147/CLEP.S156210
ER  - 
@article{
author = "Lupattelli, Angela and Twigg, Michael J. and Zagorodnikova, Ksenia and Moretti, Myla E. and Drozd, Mariola and Panchaud, Alice and Rieutord, Andre and Juraski, Romana Gjergja and Odalović, Marina and Kennedy, Debra and Rudolf, Gorazd and Juch, Herbert and Nordeng, Hedvig",
year = "2018",
abstract = "Purpose: This study aimed at exploring the prevalence of self-reported antenatal and postnatal depressive symptoms by severity across multiple countries and the association between antidepressant treatment in pregnancy and postnatal symptom severity. Materials and methods: This was a multinational web-based study conducted across 12 European countries (n=8069). Uniform data collection was ensured via an electronic questionnaire. Pregnant women at any gestational week and mothers of children with  lt 1 year of age could participate. We used the Edinburgh Postnatal Depression Scale (EPDS) to measure the prevalence of antenatal and postnatal depressive symptoms according to severity, which were corrected by survey weight adjustment (descriptive analysis). Within mothers with a psychiatric disorder (n=173), we estimated the association between antidepressant treatment in pregnancy and postnatal depressive symptom severity, as standardized EPDS mean scores, via the inverse probability of treatment weight (association analysis). Results: In the descriptive analysis (n=8069), the period prevalence of moderate-to-very severe depressive symptoms was higher in the western and eastern regions relative to the northern region, both in the antenatal period (6.8%-7.5% vs 4.3%) and in the postnatal period (7.6% vs 4.7%). One in two mothers with psychiatric disorders used an antidepressant in pregnancy (86 of 173). In the association analysis, women medicated at any time during pregnancy (adjusted beta=-0.34, 95% confidence interval [CI] =-0.66, -0.02) had a significant postnatal symptom severity reduction compared with the nonmedicated counterpart. This effect was larger (beta=-0.74, 95% CI =-1.24, -0.24) when the analysis was restricted to mothers within 6 months after childbirth. Conclusion: The prevalence of self-reported antenatal and postnatal depressive symptoms differs across European countries. Among women with psychiatric disorders, those who had been on treatment with antidepressants during pregnancy were less likely to report postnatal depressive symptoms, particularly within the 6-month period after childbirth, compared with the nonmedicated counterpart.",
publisher = "Dove Medical Press Ltd, Albany",
journal = "Clinical Epidemiology",
title = "Self-reported perinatal depressive symptoms and postnatal symptom severity after treatment with antidepressants in pregnancy: a cross-sectional study across 12 European countries using the Edinburgh Postnatal Depression Scale",
volume = "10",
pages = "655-669",
doi = "10.2147/CLEP.S156210"
}
Lupattelli, A., Twigg, M. J., Zagorodnikova, K., Moretti, M. E., Drozd, M., Panchaud, A., Rieutord, A., Juraski, R. G., Odalović, M., Kennedy, D., Rudolf, G., Juch, H.,& Nordeng, H.. (2018). Self-reported perinatal depressive symptoms and postnatal symptom severity after treatment with antidepressants in pregnancy: a cross-sectional study across 12 European countries using the Edinburgh Postnatal Depression Scale. in Clinical Epidemiology
Dove Medical Press Ltd, Albany., 10, 655-669.
https://doi.org/10.2147/CLEP.S156210
Lupattelli A, Twigg MJ, Zagorodnikova K, Moretti ME, Drozd M, Panchaud A, Rieutord A, Juraski RG, Odalović M, Kennedy D, Rudolf G, Juch H, Nordeng H. Self-reported perinatal depressive symptoms and postnatal symptom severity after treatment with antidepressants in pregnancy: a cross-sectional study across 12 European countries using the Edinburgh Postnatal Depression Scale. in Clinical Epidemiology. 2018;10:655-669.
doi:10.2147/CLEP.S156210 .
Lupattelli, Angela, Twigg, Michael J., Zagorodnikova, Ksenia, Moretti, Myla E., Drozd, Mariola, Panchaud, Alice, Rieutord, Andre, Juraski, Romana Gjergja, Odalović, Marina, Kennedy, Debra, Rudolf, Gorazd, Juch, Herbert, Nordeng, Hedvig, "Self-reported perinatal depressive symptoms and postnatal symptom severity after treatment with antidepressants in pregnancy: a cross-sectional study across 12 European countries using the Edinburgh Postnatal Depression Scale" in Clinical Epidemiology, 10 (2018):655-669,
https://doi.org/10.2147/CLEP.S156210 . .
21
12
18